Please assess the completion status of the following clinical trial:

Trial Title: Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Healthy subjects 4-17 years of age~Exclusion Criteria:~* Subjects who are not healthy,~* Subjects who are pregnant or breast feeding,~* Subjects with a history of severe allergic reaction or allergic to any of the vaccine components.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- TIVc (Type: EXPERIMENTAL): Subjects ≥4 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.
- TIVf (Type: ACTIVE_COMPARATOR): Subjects ≥4 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.

Based on this trial design, predict the completion outcome and termination type (if applicable).